Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

52.51USD
22 Sep 2017
Change (% chg)

$1.08 (+2.10%)
Prev Close
$51.43
Open
$51.51
Day's High
$52.58
Day's Low
$51.51
Volume
2,323,273
Avg. Vol
1,711,825
52-wk High
$52.60
52-wk Low
$37.38

Chart for

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.57
Market Cap(Mil.): $91,233.15
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 2.02

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

BRIEF-Abbott secures FDA approval for MRI-compatibility for the co's Ellipse ICD

* Abbott secures FDA approval for MRI-compatibility for the company's Ellipse ICD Source text for Eikon: Further company coverage:

Sep 22 2017

BRIEF-Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE

* Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE conditioned upon the completion of its acquisition by Abbott

Sep 18 2017

BRIEF-Abbott announces extension of cash tender offer

* Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc.

Sep 18 2017

BRIEF-Abbott sets quarterly dividend of $0.265 per share

* Sets quarterly dividend of $0.265 per share Source text for Eikon: Further company coverage:

Sep 14 2017

BRIEF-Abbott Laboratories says ‍NHS Business Services Authority approved listing on Drug Tariff for FreeStyle Libre system

* Abbott Laboratories - ‍NHS Business Services Authority approved listing on Drug Tariff for FreeStyle Libre system for people with diabetes using insulin​

Sep 13 2017

BRIEF-Abbott extends cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere

* Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere

Sep 01 2017

BRIEF-Abbott initiates study of AMPLATZER device to correct congenital heart defect in newborns

* Abbott initiates ground-breaking U.S. pivotal study of AMPLATZER device to correct common congenital heart defect in newborns

Aug 30 2017

Abbott releases new round of cyber updates for St. Jude pacemakers

NEW YORK Abbott Laboratories said on Tuesday it would issue updates to reduce the risk of its St. Jude heart implants being hacked and to warn patients that the devices' batteries may run down earlier than expected.

Aug 29 2017

UPDATE 2-Abbott releases new round of cyber updates for St. Jude pacemakers

NEW YORK, Aug 29 Abbott Laboratories said on Tuesday it would issue updates to reduce the risk of its St. Jude heart implants being hacked and to warn patients that the devices' batteries may run down earlier than expected.

Aug 29 2017

Abbott releases new round of cyber updates for St. Jude pacemakers

NEW YORK, Aug 29 Abbott Laboratories said on Tuesday it will issue updates to reduce the risk of its St. Jude heart implants being hacked and to warn patients that the devices' batteries may run down earlier than expected.

Aug 29 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $131.39 -0.36
Pfizer Inc. (PFE.N) $35.96 -0.01
Novartis AG (NOVN.S) CHF83.45 +0.50
Merck & Co., Inc. (MRK.N) $65.13 -0.47
Sanofi SA (SASY.PA) €84.12 +0.25
AstraZeneca plc (AZN.L) 4,912.00 +143.50
GlaxoSmithKline plc (GSK.L) 1,474.00 +6.00
Eli Lilly and Co (LLY.N) $83.91 +0.58
Amgen, Inc. (AMGN.OQ) $185.76 -0.88
Boston Scientific Corporation (BSX.N) $28.85 +0.09

Earnings vs. Estimates